自身免疫性溶血性贫血治疗进展及适应证选择  

Progress towards therapies for disease and the choice of indications in autoimmune hemolytic anemia

作　　者：付蓉[1] 于虹[1] FU Rong;YU Hong(Department of Hematology,Tianjin Medical University General Hospital,Tianjin,300052,China)

机构地区：[1]天津医科大学总医院血液科,天津300052

出　　处：《临床血液学杂志》2023年第11期768-772,共5页Journal of Clinical Hematology

摘　　要：自身免疫性溶血性贫血是一组异质性疾病,需要进行全面的实验室检查,以明确诊断并确定亚型后选择治疗方案。无论是初诊还是复发、难治患者,均应全面评估疾病性质及患者体能等以选择合适的治疗药物。目前,最佳治疗方法仍有待探索,多种新型靶向药物已出现,多项临床试验亦在进行,未来会改善难治性自身免疫性溶血性贫血患者的预后,但也将面临如何确定适应证及如何优化使用等多重挑战,以实现从经验到精准的治疗策略转变。Autoimmune hemolytic anemia(AIHA)is a heterogeneous group of diseases that need exact diagnosis of the subtype is required to select the appropriate treatment.For most AIHAs,the choice of optimal therapy remains to be found.Novel agents targeting B-cells,extravascular hemolysis,removing IgG,or complement and prospective clinical trials will make it possible to individualize therapy in the relapsed/refractory settings.Therefore,optimal selection of therapy based on AIHA type,disease profile and patient characteristics will realize a shift from experience to precise treatment strategies in the future.

关 键 词：溶血性贫血 治疗 进展 适应证 

分 类 号：R556.6[医药卫生—血液循环系统疾病]